Connect with us

Hi, what are you looking for?

Medicine

Tetra Bio-Pharma: Positive Clinical Data From Both Phase 2 Clinical Trials of QIXLEEF for Cancer Pain

Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development announced on Monday that it produced positive initial clinical data from its ongoing Phase 2 clinical trials of QIXLEEF™ (REBORN©1 and PLENITUDE©), which is a botanical inhaled investigational new drug with a fixed ratio of THC and CBD, that meets USA cGMP regulatory requirements.

The REBORN©1 trial is a head-to-head, open-label, crossover phase 2 study against oral opioids in the management of short and frequent episodes of incapacitating pain (breakthrough pain) in patients with cancer. The REBORN©1 study protocol …

Full story available on Benzinga.com

Original Article: benzinga.com

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Medicine

Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to...

Arts

The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu Arjun’s Pushpa Is Out… The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu...

Arts

Kyle Rittenhouse testifies about Gaige Grosskreutz holding a gun toward him during his trial at the Kenosha County Courthouse on November 10, 2021 in...

Medicine

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC, the “Company”)), a biotechnology company with operations in China and the...

ONBP.com